# Ticker Notes

Per-ticker running dossier. Each section is bounded to ~15 lines: rewrite
the **Thesis** line when a new catalyst moves it; append catalyst and
trade rows. Sections are read by pre-market.md, trade.md, market-open.md,
and weekly-review.md via scripts/research.py ticker-notes <SYM>.

Conventions:
- Cite sources inline with [outlet] tags.
- Dates in ISO format (YYYY-MM-DD).
- The OPEN catalyst list keeps the last 5 entries; older rows get archived
  to memory/TICKER-NOTES-ARCHIVE.md during the weekly review.
- Trade-outcome rows mirror the canonical CLOSED-line metadata.

<!-- SEED-CURSOR: AAPL -->

---

## MU (XLK)
- Thesis (2026-06-12): Demoted 5th consecutive session — at $995.87, R:R on the only level above consensus (52w-high $1,089.29) is just 0.63:1 against the 15%-clamped ATR stop; consensus median $637.50 (40 analysts) is 36% below price. Goldman flagged "high bar" caution into 06-24 earnings (12d out). Iran de-escalation (Trump cancelled strikes) is a tailwind removing tail-risk, but doesn't fix the valuation/consensus gap. Do NOT chase. [Demoted: R:R 0.63:1. analyst_data.py + Finnhub Jun 12]
- Recent catalysts:
  - 2026-06-12: Goldman cautious into 06-24 earnings ("high bar"); memory stocks (MU/STX/WDC/SNDK) rallied on Iran peace-deal hopes + DRAM/NAND price-hike thesis [Finnhub Jun 12]
  - 2026-06-09: small insider BUY (Bjorlin, 63sh, immaterial) [Finnhub Jun 12]
  - 2026-06-08: +7.1% premarket on SK Hynix-NVDA HBM deal headline; still fails R:R at both chase and no-chase prices [Barron's Jun 8]
  - 2026-06-07: CEO Mehrotra sold ~40,000 sh (~$38M, pre-planned 10b5-1) [Motley Fool Jun 7]
  - 2026-06-24: Q4 FY2026 earnings report (next — 12d; key re-entry catalyst, "could go parabolic" per Motley Fool)
  <!-- archive: 2026-06-05: Screener #1 (ml 1.36) but demoted — R:R 0.87:1; hot NFP +251K adds yield pressure -->
  <!-- archive: 2026-06-03: Morgan Stanley raises MU PT to $1,050; Susquehanna to $1,750 (5/29) -->
  <!-- archive: 2026-06-04: AVGO AH infra-software miss; MU trailing stop hit $986.18 at 13:59 ET -->
  <!-- archive: 2026-06-02/05: COMPUTEX 2026 Taipei (Jensen Huang keynote HBM4 + Vera Rubin) -->
- Trade history:
  - 2026-06-04: r=0.45, regime=Neutral, reason="trailing stop hit on AVGO software miss contagion; HBM thesis intact, catalyst-specific break; peak was +1.25R (HWM $1,088) but 9.47% trail left too much gap-down room"
- Open thesis questions:
  - Consensus median ($637.50) sits 36% below price — structural mismatch unchanged for 2 weeks. What would move the Street consensus up enough (or price down enough) to clear 2:1?
  - Does 06-24 earnings (Goldman "high bar") become the volatility event that either validates a pullback entry or confirms the bear case?
  - Iran de-escalation removes a tail-risk overhang — does this matter if the consensus/valuation gate is the binding constraint regardless?

## AMD (XLK)
- Thesis (2026-06-12): Demoted — R:R 0.98:1 even using BofA's brand-new $560 PT (Vivek Arya, 06-11, "top CPU pick" on $170B 2030 server-CPU TAM), vs ATR-clamped 15% stop ($415.18). AMD +8% Thu (06-11) to $488.45 on the BofA call + broad Iran-de-escalation chip rally; this is the level AMD was trading at before the prior held position's exit (entry was $493.80, exited 06-09/06-10 on thesis-break). Stale 48-analyst consensus ($487.50 median) doesn't yet reflect BofA's raise — single-bank call, not yet broad re-rating. Close but still fails 2:1. [Demoted: R:R 0.98:1. WebSearch + analyst_data.py Jun 12]
- Recent catalysts:
  - 2026-06-11: BofA (Vivek Arya) raised PT $500→$560, reiterated Buy, "top CPU pick" on $170B 2030 server-CPU TAM (agentic AI demand) — AMD +8% to $488.40 [TipRanks/247WallSt Jun 11]
  - 2026-06-10: ARK (Cathie Wood) trimmed AMD, added NVDA same week [Motley Fool Jun 10]
  - 2026-06-02: small insider SELLs (Denzel Nora 06-02/05-29, Norrod Forrest 05-20) — routine pattern, not new signal [Finnhub Jun 12]
  <!-- archive: 2026-06-04: AVGO sell-the-news contagion; AMD −3.97% sympathetic -->
  <!-- archive: 2026-06-03: Analyst upgraded to Strong Buy; stock hits all-time high $540.94 -->
  <!-- archive: 2026-06-03: Director sold $5.4M near all-time highs -->
  <!-- archive: 2026-06-01: Mizuho PT raised $515→$615, "Outperform" maintained -->
  <!-- archive: 2026-06-02: Radeon RX 9070 GRE global launch + BofA Tech Conference + Microsoft Build -->
- Trade history:
  - Position exited 06-09/06-10 (TRADE-LOG gap, no entry recorded — thesis-break per 06-08 notes: COMPUTEX exhaustion + NFP yield spike + AVGO contagion)
- Open thesis questions:
  - Will other sell-side desks follow BofA's $560 PT within the next week (validating the re-rating) or does the +8% Thu pop mean-revert toward $460-470?
  - If AMD pulls back toward the $440s while $560 PT holds, R:R approaches ~1.8:1 — still short of 2.0 but worth a price-alert re-check.
  - Single most-likely invalidator: no follow-through from other analysts on the BofA upgrade within 5 trading days.

---

## AAPL (XLK)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## AMZN (XLY)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## AVGO (XLK)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## BA (XLI)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## CAT (XLI)
- Thesis (2026-06-05): **HOLD, INTACT** — Data center power re-rating thesis fully insulated from NFP + semiconductor pressure. CAT −0.8% to $933 premarket (XLI/industrials resilience vs XLK −3.4%). Trail 7.97% HWM=$946.83 stop=$871.37 (6.6% buffer). Hot NFP +251K is CAT-supportive (strong labor = strong capex spending = data center buildout continues). Stop locks in +$3.66/sh gain (stop $871.37 > entry $867.71). No change to position; thesis intact.
- Recent catalysts:
  - 2026-06-04: Sector-wide pullback (AVGO contagion) did NOT impact CAT; +1.52% Jun 4 shows thesis isolation; consolidation into NFP [Jun 4]
  - 2026-Q1: Record backlog $63B (+79% YoY); EPS +30% YoY; raised guidance
  - 2026-05: Analyst upgrades — JPM $1,125, Argus $990, Morgan Stanley $915, DA Davidson $845
  - 2026-06: Annual dividend increase expected (32nd consecutive)
- Open thesis questions:
  - Q1 tariff costs $710M — will US-China escalation compound in Q2?
  - Resource Industries profit −39% YoY; can data center power fully offset?
  - XLI sector Choppy (regime score 0.054); sector tailwind absent — thesis is CAT-specific not sector
  - Single most-likely invalidator: US-China tariff escalation targeting industrial machinery category

## COST (XLP)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## CVX (XLE)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## DIA (BROAD)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## DIS (XLC)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## GOOGL (XLC)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## HD (XLY)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## IWM (BROAD)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## JNJ (XLV)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## JPM (XLF)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## KO (XLP)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## LLY (XLV)
- Thesis (2026-06-11): At 1.85% off the 52w high ($1,182.73) and 41.2x trailing/26.1x fwd P/E, GLP-1 leadership is fully priced in. Consensus PT median $1,251 (BofA 05-26) implies only +7.7%, vs a real 7.95% ATR stop → R:R 0.98:1, fails 2:1 floor (even Truist's $1,281 only reaches 1.30:1). Continued bullish flow (Citi "compelling" note, oral GLP-1 diabetes data beating Novo/AZ, fresh 52w high) but no valuation cushion. Demoted on math, not thesis. [Demoted: R:R 0.98:1. analyst_data.py + WebSearch Jun 11]
- Recent catalysts:
  - 2026-06-11 [Seeking Alpha]: 1-in-10 employers may drop GLP-1 coverage in 2027 — multi-year pricing tail risk
  - 2026-06-09 [Yahoo Finance]: LLY hit fresh 52-week high alongside AAPL/OSCR
  - 2026-06-08 [Yahoo Finance]: Oral GLP-1 pill data beat Novo Nordisk/AstraZeneca diabetes trial readouts
  - 2026-06-08 [TipRanks/Citi]: Citi reiterates bullish "This Is Compelling" note
  - 2026-05-26 [BofA Securities]: PT raised to $1,251 from $1,133 (Buy); Truist $1,281 Buy (May 21)
  <!-- archive: 2026-05-27 ASCO/ADA catalyst confirmed; 2026-05-22 retatrutide 12mg tolerability risk; 2026-05-21 TRIUMPH-1 positive; 2026-05-19 Barclays NVO oral Wegovy note; 2026-05-26 Endowment $577M routine -->
- Open thesis questions:
  - FDA/court ruling on compounded GLP-1 availability — could materially impair pricing and revenue
  - Employer GLP-1 coverage pullback for 2027 — how material to revenue if it spreads beyond early adopters?
  - Would need a fresh PT raise above ~$1,260 (vs current $1,251 median) to clear 2:1 against the 7.95% stop — watch for post-ADA analyst updates
- Trade history: (none yet)
- Position-aware notes: 0% XLV exposure (no open positions as of 06-11). LLY > $1,060 gate cleared (now $1,160.80) — gate is no longer the blocker, R:R math is.

## MA (XLF)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## META (XLC)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## MRK (XLV)
- Thesis (2026-06-08): Within 3.5% of 52w high ($125.14); 29-analyst Buy consensus (avg PT $129.74-136.50, ~7-13% upside) clears the credible-target bar at only R:R 1.86:1 — fails the 2.0 floor. Only the outlier-high $150 estimate (top of a $100-150 range) produces ≥2:1, which the B3 audit specifically flags as a cherry-picking error. Pipeline catalysts (Cidara/CD388, Winrevair Phase 2, ASCO intismeran autogene data) are real but already-priced; Keytruda patent-cliff overhang capped the stock at -3.19% as recently as 6/1. Best non-XLK/XLI diversification (corr -0.02 vs CAT) but math doesn't clear. Demoted. [Demoted: R:R 1.86:1 on consensus target. WebSearch/S&P Global Jun 8]
- Recent catalysts:
  - 2026-06-08: 29-analyst Buy consensus avg PT $129.74 (S&P Global); pipeline: Cidara/CD388 acquisition, Winrevair Phase 2 CADENCE positive topline, ASCO 5-yr intismeran autogene + Keytruda melanoma data [WebSearch Jun 8]
  - 2026-06-01: -3.19% single-session move — Keytruda biosimilar/patent-cliff overhang remains live even in a "Trend"-tagged sector [TradingKey Jun 1]
- Open thesis questions:
  - Can MRK clear its own $125.14 52w high on the dated pipeline catalyst flow, or does the Keytruda-cliff overhang keep capping it below the consensus PT range?
  - Is the $150 high-end analyst estimate ever a defensible 2:1 target, or does it stay an outlier vs. the $129-136 consensus the Street actually believes?
- Trade history: (none yet)
- Position-aware notes: XLV currently 0% exposure (fresh sector if entered); near-zero correlation with AMD/CAT (-0.02) — best factor diversification of any candidate screened to date.

## MS (XLF)
- Thesis (2026-06-11): Still demoted — consensus PT median $205/mean $203.29 (21 analysts) is BELOW spot $208.30 (implies -1.6%/-2.4%, auto-fail B3). Even the lone bull PT $230 (KBW) only gives 1.49:1 against the 7% floor stop ($193.72). 5% off 52w high $219.16. No fresh analyst action since 06-08; data unchanged. [Demoted: consensus-implied negative + 1.49:1 best-case. analyst_data.py Jun 11]
- Recent catalysts:
  - 2026-06-09: Annual U.S. Financials Conference (CEO Ted Pick spoke) — no PT-moving guidance surfaced yet
  - 2026-06-08: Confirmed still trading above its own consensus PT range; KBW (Konrad) sole bull at $230/+8.6% [Benzinga/MarketBeat via WebSearch]
  - 2026-06-02: $33M Subtle Medical (AI medical imaging) investment led by MS Investment Mgmt
  <!-- archive: none -->
- Open thesis questions:
  - Consensus PT $203-205 < current $208.30 — needs a fresh analyst upgrade above ~$236 (+13%) to make the 7%-floor-stop math work at 2:1
  - XLF sector Choppy (not Bear) — clears the hard filter, but provides no directional tailwind to close the PT gap
  - Did the 06-09 Financials Conference produce any forward guidance that could move sell-side targets? (NewsAPI returned only ticker-collision noise on 06-11)

## MSFT (XLK)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## NFLX (XLC)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## NVDA (XLK)
- Thesis (2026-05-27): MU +19% premarket (HBM sold out 2027, HBM4 shipping for Vera Rubin) re-validates AI infrastructure demand chain; NVDA Q1 FY27 beat ($81.6B +85% YoY) + Q2 guide $91B intact; institutional sell-the-news pressure from ER now counterbalanced by supply chain confirmation. COMPUTEX June 1 (Jensen Huang keynote) = next major catalyst. 30y yield 5.01% (gate passed). Conviction: high.
- Recent catalysts:
  - 2026-05-27 [Micron IR / Gemini grounded]: MU Q3 FY26 guidance $33.5B rev (+250% YoY), 81% GM; HBM sold out 2027; HBM4 volume shipments for NVDA Vera Rubin confirmed
  - 2026-05-27 [TD Cowen / BofA confirmed]: NVDA presenting TMT Conference May 28; COMPUTEX GTC Taipei June 1 (Jensen Huang keynote); BofA Global Tech Conference June 4
  - 2026-05-26 [Gemini grounded]: PT wave: Goldman $285, HSBC $325, Truist $307, Craig Hallum $275, Citic $315
  - 2026-05-20 [NVDA IR]: Q1 FY27 beat: rev $81.6B, DC $75.2B (+92%), EPS $1.87; Q2 guide $91B; $80B buyback + 25× dividend
  <!-- archive: 2026-05-22 sell-the-news −3.6%; 2026-05-21 PT wave; 2026-05-25 export risk flagged -->
- Open thesis questions:
  - COMPUTEX June 1: does Jensen Huang announce Vera Rubin timing acceleration or new AI factory deals?
  - AVGO June 3 ER: confirms AI capex 2H ramp?
  - Post-PCE (May 28): does benign PCE resolve institutional sell pressure?
  - Kill-switch: 30y yield > 5.15% → skip entry
- Trade history: (none yet)
- Position-aware notes: sector cap=2 → NVDA + 1 other XLK max. Correlation with LLY = −0.42. Entry gate today: 30y 5.01% ✓ + NVDA > $213 ✓.

## PG (XLP)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## QQQ (BROAD)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## SPY (BROAD)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## TSLA (XLY)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## UNH (XLV)
- Thesis (2026-06-08): Sentiment has flipped sharply bullish (BofA upgrade to Buy, dividend +5%, Q1 beat+raise, "40% rally" headlines, stock now $399.47 — near its $404 52w high) — but the active DOJ criminal investigation into Medicare billing remains OPEN/UNRESOLVED per fresh confirmation (no charges yet, no announced resolution timeline). Improving fundamentals do not retire a binary federal-indictment gap-risk that no stop protects against. 7th consecutive drop on the same DOJ basis (6/2 through 6/8). [Dropped — DOJ binary risk unchanged. WebSearch Jun 8; healthcaredive/fiercehealthcare]
- Recent catalysts:
  - 2026-06-08: BofA Securities upgrade to "Buy" + 5% dividend raise drove a fresh pop; stock near 52w high $404.15, up ~40% from recent lows [Barchart/TIKR via WebSearch Jun 8]
  - Ongoing (confirmed still active 6/8): DOJ criminal + civil investigation into Medicare Advantage/Optum Rx/physician-reimbursement billing practices — no charges, no resolution timeline [healthcaredive.com, fiercehealthcare.com via WebSearch Jun 8]
  - 2026-Q1: Adj EPS $7.23 beat; FY2026 guidance raised >$18.25; prior authorization cuts for 30% of services
  <!-- archive: 2026-05: Truist PT raised to $440; median consensus PT $400.50 -->
- Open thesis questions:
  - DOJ criminal investigation: indictment risk → gap-down 15-30%; unmanageable with trailing stop. Does the bullish sentiment wave (BofA upgrade, dividend hike) eventually outweigh this in the bot's framework, or does the binary-risk gate hold indefinitely until the investigation formally resolves?
  - At what point does a 7-session string of identical DOJ-based drops warrant a strategy-level rule (e.g., a standing "no entry while active criminal probe" filter) vs. re-litigating it daily?
  - MLR still elevated; membership down 2.8M in 2026 — does the rally reflect real operational improvement or short-covering/legal-resolution optimism getting ahead of facts?

## UNP (XLI)
- Thesis (2026-06-04): XLI Trend regime; Q1 FY2026 EPS $2.87 (+5.9% YoY), revenue $6.22B (+3.2%); Norfolk Southern integration potential PT uplift; consensus PT $273.36 (26 analysts), Barclays outlier $315 (Apr 24, 2026); current $262.13. DEMOTED — R:R 0.96:1 with year-high $279.70 as target fails 2.0 floor; entry only viable if price retraces to ~$245–250.
- Recent catalysts:
  - 2026-Q1: EPS $2.87, revenue $6.22B (+3.2%); analyst PT wave higher
  - 2026-04-24: Barclays raises PT to $315 [MarketBeat via WebSearch]
- Open thesis questions:
  - Norfolk Southern deal progress — updates at Q2 earnings Jul 23?
  - Freight volume sensitivity to US-China tariff regime?

## V (XLF)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## WMT (XLP)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## XLB (XLB)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## XLC (XLC)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## XLE (XLE)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## XLF (XLF)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## XLI (XLI)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## XLK (XLK)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## XLP (XLP)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## XLRE (XLRE)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## XLU (XLU)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## XLV (XLV)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## XLY (XLY)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

## XOM (XLE)
- Thesis (uninitialized): seed entry; pre-market will rewrite on first run.
- Recent catalysts: (none yet)
- Open thesis questions: (none yet)
- Trade history: (none yet)
- Position-aware notes: (none yet)

